Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 10,525 matching trials from the live ClinicalTrials.gov search.

Filters: Active, not recruiting Clear all

Conditions: Metabolic Syndrome, Breast Cancer Prevention, Physical Activity
Interventions: Enhanced physical activity monitor which is Fitbit watch with mobile App, Bollywood-style group dance, PAMDance; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • Sugar Grove, Illinois

Conditions: Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
Interventions: Evolocumab, Routine Lipid Management; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 6,019 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 81
States / cities: Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 73 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: MN-166, placebo; Drug
Lead sponsor: MediciNova; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 10
States / cities: Orange, California • Jacksonville, Florida • Augusta, Georgia + 7 more

Conditions: Prostate Cancer
Interventions: Stereotactic Body Radiotherapy; Radiation
Lead sponsor: Linda Chan, MD; Other
Eligibility: Male only
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Laguna Hills, California

Conditions: Asthma
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 1,339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 75
States / cities: Cullman, Alabama • Sheffield, Alabama • Chandler, Arizona + 66 more

Conditions: Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Anemia
Interventions: ACE-536, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 14
States / cities: Los Angeles, California • Orlando, Florida • Plantation, Florida + 10 more

Conditions: Unintended Pregnancy, Undesired Pregnancy
Interventions: Pregnancy preferences (Aim 1), Sociocultural environment (Aim 2), Pregnancy preferences (Aim 3a), Pregnancy (Aim 3b); Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 15 Years to 34 Years · Female only
Enrollment: 2,015 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Oakland, California

Conditions: DCIS, Ductal Carcinoma in Situ
Interventions: Surgery, Active Monitoring; Other
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 40 Years to 99 Years · Female only
Enrollment: 997 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 141
States / cities: Anchorage, Alaska • Phoenix, Arizona • Duarte, California + 117 more

Conditions: Plantar Fascitis
Interventions: Radial shockwave therapy, Focused shockwave therapy, Shockwave therapy device, Home therapy; Procedure · Device · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 100 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Small Cell Lung Cancer
Interventions: Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Olaparib 300 mg BID, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice, Standard Thoracic Radiotherapy, Prophylactic Cranial Irradiation (PCI); Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 35
States / cities: Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more

Conditions: High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma
Interventions: Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide; Biological · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 124
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 100 more

Conditions: Cervical Disc Disease
Interventions: BAGUERA®C Cervical Disc Prosthesis, Mobi-C Cervical Disc; Device
Lead sponsor: Spineart USA; Industry
Eligibility: 22 Years to 69 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 26
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Laguna Hills, California + 23 more

Conditions: Health Knowledge, Attitudes, Practice
Interventions: Online educational phthalate course, Control environmental education, Phthalate conversation, Environmental exposures conversation; Behavioral
Lead sponsor: Harvard School of Public Health (HSPH); Other
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
Interventions: ALK-001; Drug
Lead sponsor: Alkeus Pharmaceuticals, Inc.; Industry
Eligibility: 8 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 8
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 5 more

Conditions: Drinking Behavior
Interventions: Sequential Personalized Feedback Intervention Delivery, Simultaneous Personalized Feedback Intervention Delivery, Text Message Boosters; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 24 Years
Enrollment: 1,012 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
Interventions: Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo; Drug · Other
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 6 Years to 28 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Seattle, Washington

Conditions: Persistent Atrial Fibrillation
Interventions: Sphere-9™ Catheter and Affera™ Ablation System; Device
Lead sponsor: Medtronic Cardiac Ablation Solutions; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 14
States / cities: Birmingham, Alabama • Sarasota, Florida • Atlanta, Georgia + 11 more

Conditions: Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma
Interventions: Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL); Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Neonatal Encephalopathy
Interventions: Transcutaneous Carbon Dioxide Monitoring; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 0 Days to 3 Days
Enrollment: 53 participants
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV
Interventions: SB-728mR-HSPC Infusion 3 days following busulfan conditioning; Genetic
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 5
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 1 more

Conditions: Diabetic Foot Ulcers
Interventions: Antimicrobial Peptide PL-5 Topical Spray and Placebo; Drug
Lead sponsor: Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Vista, California • Miami, Florida • Tampa, Florida

Conditions: Headache, Headache Disorders, Headache, Migraine, Migraine, Migraine Disorders, Migraine With Aura, Migraine Without Aura, Chronic Migraine
Interventions: 40 minute session, 20 minute session, home practice e-health, home practice handout, phone call; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 10 Years to 17 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Aurora, Colorado • Cincinnati, Ohio

Conditions: Metastatic Breast Cancer
Interventions: Lenvatinib, Pembrolizuma, Fulvestrant; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Child Maltreatment, Child Exposure to Intimate Partner Violence
Interventions: Enhanced First Connections; Behavioral
Lead sponsor: Bradley Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: East Providence, Rhode Island

Search by objective public record fields.

Physical Activity Targeting Metabolic Syndrome for Prevention of Breast Cancer in SAI Women

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Attitudes and Decision-making After Pregnancy Testing Study

Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS

Shockwave Therapy for Plantar Fasciitis RCT

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

A Clinical Trial Comparing the BAGUERA C to the Marketed Mobi-C® for the Treatment of Cervical Disc Disease at 2 Contiguous Levels

Doulas as Environmental Educators and Partners Study

Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

Motivating Campus Change Study

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

SPHERE Per-AF Post-Approval Study

Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC

Transcutaneous Carbon Dioxide Monitoring in Neonates Receiving Therapeutic Hypothermia for Neonatal Encephalopathy

Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients

Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers

Mind Body Balance for Pediatric Migraine

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Prevention of Childhood Maltreatment in Families With Young Children